86 related articles for article (PubMed ID: 3965633)
41. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
42. Treatment results of tonsillar lymphoma: a 10-year experience.
Mohammadianpanah M; Omidvai S; Mosalei A; Ahmadloo N
Ann Hematol; 2005 Apr; 84(4):223-6. PubMed ID: 15042316
[TBL] [Abstract][Full Text] [Related]
43. Results of treatment with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) for non-Hodgkin's aggressive lymphoma analyzed according to the International Prognostic Index.
Aydin F; Ulusoy S; Ovali E
J Chemother; 1997 Dec; 9(6):446-51. PubMed ID: 9491847
[TBL] [Abstract][Full Text] [Related]
44. The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab.
Park JH; Yoon DH; Kim DY; Kim S; Seo S; Jeong Y; Lee SW; Park CS; Huh J; Suh C
Ann Hematol; 2014 Oct; 93(10):1755-64. PubMed ID: 25027115
[TBL] [Abstract][Full Text] [Related]
45. Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy.
Hausdorff J; Davis E; Long G; Hoppe R; van der Pas M; Lassman C; Kamel O; Jacobs C
Cancer J Sci Am; 1997; 3(5):303-11. PubMed ID: 9327155
[TBL] [Abstract][Full Text] [Related]
46. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis.
Kwak LW; Halpern J; Olshen RA; Horning SJ
J Clin Oncol; 1990 Jun; 8(6):963-77. PubMed ID: 2348230
[TBL] [Abstract][Full Text] [Related]
47. Primary bone marrow diffuse large B cell lymphoma: a case series and review.
Chang H; Hung YS; Lin TL; Wang PN; Kuo MC; Tang TC; Wu JH; Dunn P; Shih LY
Ann Hematol; 2011 Jul; 90(7):791-6. PubMed ID: 21181164
[TBL] [Abstract][Full Text] [Related]
48. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
Lim ST; Karim R; Nathwani BN; Tulpule A; Espina B; Levine AM
J Clin Oncol; 2005 Jul; 23(19):4430-8. PubMed ID: 15883411
[TBL] [Abstract][Full Text] [Related]
49. Group risk classification of non-Hodgkin's lymphoma.
Avilés A; Díaz-Maqueo JC; Rodríguez L; García EL; Torras V; Guzmán R
Arch Invest Med (Mex); 1990; 21(1):11-6. PubMed ID: 1699503
[TBL] [Abstract][Full Text] [Related]
50. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
51. Large-cell and immunoblastic lymphoma of the mediastinum: prognostic features and treatment outcome in 57 patients.
Kirn D; Mauch P; Shaffer K; Pinkus G; Shipp MA; Kaplan WD; Tung N; Wheeler C; Beard CJ; Canellos GP
J Clin Oncol; 1993 Jul; 11(7):1336-43. PubMed ID: 8315431
[TBL] [Abstract][Full Text] [Related]
52. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels.
Swan F; Velasquez WS; Tucker S; Redman JR; Rodriguez MA; McLaughlin P; Hagemeister FB; Cabanillas F
J Clin Oncol; 1989 Oct; 7(10):1518-27. PubMed ID: 2674337
[TBL] [Abstract][Full Text] [Related]
53. Diffuse large cell lymphoma with discordant bone marrow histology. Clinical features and biological implications.
Fisher DE; Jacobson JO; Ault KA; Harris NL
Cancer; 1989 Nov; 64(9):1879-87. PubMed ID: 2790699
[TBL] [Abstract][Full Text] [Related]
54. Serum lactate dehydrogenase (LDH) as a prognostic index for non-Hodgkin's lymphoma.
Endrizzi L; Fiorentino MV; Salvagno L; Segati R; Pappagallo GL; Fosser V
Eur J Cancer Clin Oncol; 1982 Oct; 18(10):945-9. PubMed ID: 6891644
[TBL] [Abstract][Full Text] [Related]
55. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma.
Dimopoulos MA; Barlogie B; Smith TL; Alexanian R
Ann Intern Med; 1991 Dec; 115(12):931-5. PubMed ID: 1952489
[TBL] [Abstract][Full Text] [Related]
56. Prognostic significance of serum lactate dehydrogenase in malignant lymphoma.
Schneider RJ; Seibert K; Passe S; Little C; Gee T; Lee BJ; Miké V; Young CW
Cancer; 1980 Jul; 46(1):139-43. PubMed ID: 6992974
[TBL] [Abstract][Full Text] [Related]
57. American Burkitt's lymphoma: a clinicopathologic study of 30 cases. I. Clinical factors relating to prolonged survival.
Arseneau JC; Canellos GP; Banks PM; Berard CW; Gralnick HR; DeVita VT
Am J Med; 1975 Mar; 58(3):314-21. PubMed ID: 1115074
[TBL] [Abstract][Full Text] [Related]
58. Large-cell lymphoma: a study of prognostic factors and assessment of five recently proposed predictive systems.
Lopez-Guillermo A; Montserrat E; Reverter JC; Cervantes F; Escoda L; Tassies D; Blade J; Marin P; Sierra J; Ordi J
Leuk Lymphoma; 1993 May; 10(1-2):101-9. PubMed ID: 8374517
[TBL] [Abstract][Full Text] [Related]
59. Treatment of advanced diffuse histiocytic lymphoma: an analysis of prognostic variables.
Koziner B; Little C; Passe S; Thaler HT; Sklaroff R; Straus DJ; Lee BJ; Clarkson BD
Cancer; 1982 Apr; 49(8):1571-9. PubMed ID: 7066863
[TBL] [Abstract][Full Text] [Related]
60. Surgical debulking is associated with improved survival in stage I-II diffuse large cell lymphoma.
Romagurea JE; Velasquez WS; Silvermintz KB; Fuller LB; Hagemeister FB; McLaughlin P; Cabanillas F
Cancer; 1990 Jul; 66(2):267-72. PubMed ID: 2369711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
